Assessment of mucosal immunity to HIV-1

References

• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361, 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Wirthner D, Schiller JT et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl Cancer Inst.95, 1128–1137 (2003).
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Garcia-Pineres A, Falk RT et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine26, 3608–3616 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider JA, Alam SA, Ackers M et al. Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J. Infect. Dis.196, 1637–1644 (2007).
   PubMedGoogle Scholar
• Cummins JE Jr, Doncel GF. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex. Transm. Dis.36, S84–S91 (2009).
   Web of Science ®Google Scholar
• Keller MJ, Herold BC. Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex Transm. Dis.36, S92–S95 (2009).
   PubMedGoogle Scholar
• Pala P, Gomez-Roman VR, Gilmour J, Kaleebu P. An African perspective on mucosal immunity and HIV-1. Mucosal Immunol.2, 300–314 (2009).
   PubMedGoogle Scholar
• Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat. Rev. Immunol.8, 447–457 (2008).
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet372, 1881–1893 (2008).
   PubMed Web of Science ®Google Scholar
• Benlahrech A, Harris J, Meiser A et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl Acad. Sci. USA106, 19940–19945 (2009).
   PubMed Web of Science ®Google Scholar
• Walker BD, Burton DR. Toward an AIDS vaccine. Science320, 760–764 (2008).
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med.15, 866–870 (2009).
   PubMed Web of Science ®Google Scholar
• Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J. Intern. Med.262, 44–58 (2007).
   PubMedGoogle Scholar
• Piacentini L, Fenizia C, Naddeo V, Clerici M. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine26, 3002–3007 (2008).
   PubMed Web of Science ®Google Scholar
• Horton RE, Ball TB, Wachichi C et al. Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res. Hum. Retroviruses25, 83–92 (2009).
   PubMedGoogle Scholar
• McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol.10, 11–23 (2009).
   PubMedGoogle Scholar
• Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-γ-dependent RANTES production following a vaginal viral challenge. Am. J. Reprod. Immunol.46, 420–424 (2001).
   PubMedGoogle Scholar
• Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol.80, 5283–5291 (2006).
   PubMed Web of Science ®Google Scholar
• Villavedra M, Carol H, Hjulstrom M, Holmgren J, Czerkinsky C. “PERFEXT”: a direct method for quantitative assessment of cytokine production in vivo at the local level. Res. Immunol.148, 257–266 (1997).
   PubMedGoogle Scholar
• Devito C, Zuber B, Schroder U et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol.173, 7078–7089 (2004).
   PubMed Web of Science ®Google Scholar
• Parr EL, Parr MB. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J. Virol.72, 5137–5145 (1998).
   PubMed Web of Science ®Google Scholar
• Jiang JQ, Patrick A, Moss RB, Rosenthal KL. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J. Virol.79, 393–400 (2005).
   PubMed Web of Science ®Google Scholar
• Garulli B, Kawaoka Y, Castrucci MR. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J. Virol.78, 1020–1025 (2004).
   PubMedGoogle Scholar
• Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D. Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4(+) and CD8(+) T cells in the genital and intestinal tracts. Vaccine28(5), 1226–1233 (2009).
   PubMedGoogle Scholar
• Lindqvist M, Navabi N, Jansson M et al. Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine28, 270–278 (2009).
   PubMedGoogle Scholar
• Blish CA, Sather DN, Sellhorn G et al. Comparative immunogenicity of subtype a human immunodeficiency virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J. Virol.84(5), 2573–2584 (2009).
   PubMedGoogle Scholar
• Zolla-Pazner S, Cohen S, Pinter A et al. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology392, 82–93 (2009).
   PubMed Web of Science ®Google Scholar
• Dey B, Svehla K, Xu L et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog.5, e1000445 (2009).
   PubMed Web of Science ®Google Scholar
• Burioni R, Mancini N, De Marco D et al. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One3, e3423 (2008).
   Google Scholar
• Barberini F, Correr S, De Santis F, Motta PM. The epithelium of the rabbit vagina: a microtopographical study by light, transmission and scanning electron microscopy. Arch. Histol. Cytol.54, 365–378 (1991).
   PubMedGoogle Scholar
• Winchell JM, Van Kruiningen HJ, Silbart LK. Mucosal immune response to an HIV C4/V3 peptide following nasal or intestinal immunization of rabbits. AIDS Res. Hum. Retroviruses13, 881–889 (1997).
   PubMedGoogle Scholar
• Zinckgraf JW, Winchell JM, Silbart LK. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide. J. Reprod. Immunol.45, 99–112 (1999).
   PubMedGoogle Scholar
• Castle PE, Rodriguez AC, Bowman FP et al. Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin. Diagn. Lab. Immunol.11, 399–405 (2004).
   PubMedGoogle Scholar
• Koopman G, Bogers WM, van Gils M et al. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J. Med. Virol.79, 474–482 (2007).
   PubMed Web of Science ®Google Scholar
• Salvato MS, Emau P, Malkovsky M et al. Cellular immune responses in rhesus macaques infected rectally with low dose simian immunodeficiency virus. J. Med. Primatol.23, 125–130 (1994).
   PubMed Web of Science ®Google Scholar
• Polyanskaya N, Bergmeier LA, Sharpe SA et al. Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody. Virology279, 527–538 (2001).
   PubMed Web of Science ®Google Scholar
• Hudgens MG, Gilbert PB, Mascola JR et al. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J. Infect. Dis.200, 609–613 (2009).
   PubMedGoogle Scholar
• Mederle I, Le Grand R, Vaslin B et al. Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine21, 4153–4166 (2003).
   PubMed Web of Science ®Google Scholar
• Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol.1, 11–22 (2008).
   PubMed Web of Science ®Google Scholar
• Kozlowski PA, Lynch RM, Patterson RR et al. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J. Acquir. Immune Defic. Syndr.24, 297–309 (2000).
   PubMedGoogle Scholar
• Caufour P, Le Grand R, Cheret A et al. Longitudinal analysis of CD8(+) T-cell phenotype and IL-7, IL-15 and IL-16 mRNA expression in different tissues during primary simian immunodeficiency virus infection. Microbes Infect.3, 181–191 (2001).
   PubMedGoogle Scholar
• Anderson DJ, Williams DL, Ballagh SA et al. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am. J. Reprod. Immunol.61, 121–129 (2009).
   PubMed Web of Science ®Google Scholar
• Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J. Acquir. Immune Defic. Syndr.37(Suppl. 3), S184–S193 (2004).
   PubMed Web of Science ®Google Scholar
• Mauck CK, Ballagh SA, Creinin MD et al. Six-day randomized safety trial of intravaginal lime juice. J. Acquir. Immune Defic. Syndr.49, 243–250 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartz JL, Mauck C, Lai JJ et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception74, 133–140 (2006).
   PubMedGoogle Scholar
• Fichorova RN, Richardson-Harman N, Alfano M et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal. Chem.80, 4741–4751 (2008).
   PubMedGoogle Scholar
• Gravitt PE, Hildesheim A, Herrero R et al. Correlates of IL-10 and IL-12 concentrations in cervical secretions. J. Clin. Immunol.23, 175–183 (2003).
   PubMed Web of Science ®Google Scholar
• Hildesheim A, McShane LM, Schiffman M et al. Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-Cel collection instrument and correlates of immune measures. J. Immunol. Methods225, 131–143 (1999).
   PubMedGoogle Scholar
• Quesnel A, Cu-Uvin S, Murphy D et al. Comparative analysis of methods for collection and measurement of immunoglobulins in cervical and vaginal secretions of women. J. Immunol. Methods202, 153–161 (1997).
   PubMed Web of Science ®Google Scholar
• Snowhite IV, Jones WE, Dumestre J et al. Comparative analysis of methods for collection and measurement of cytokines and immunoglobulins in cervical and vaginal secretions of HIV and HPV infected women. J. Immunol. Methods263, 85–95 (2002).
   PubMedGoogle Scholar
• Belec L, Meillet D, Levy M et al. Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin. Diagn. Lab. Immunol.2, 57–61 (1995).
   PubMedGoogle Scholar
• Safaeian M, Kemp T, Falk RT et al. Determinants and correlation of systemic and cervical concentrations of total IgA and IgG. Cancer Epidemiol. Biomarkers Prev.18, 2672–2676 (2009).
   PubMedGoogle Scholar
• Alexander R, Mestecky J. Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr. HIV Res.5, 588–593 (2007).
   PubMedGoogle Scholar
• Jones HE, Wiegerinck MA, Nieboer TE, Mol BW, Westhoff CL. Women in the Netherlands prefer self-sampling with a novel lavaging device to clinician collection of specimens for cervical cancer screening. Sex Transm. Dis.35, 916–917 (2008).
   PubMed Web of Science ®Google Scholar
• Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod.73, 1253–1263 (2005).
   PubMed Web of Science ®Google Scholar
• Nkwanyana NN, Gumbi PP, Roberts L et al. Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology128, e746–e757 (2009).
   Google Scholar
• Passmore JA, Milner M, Denny L et al. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology119, 507–514 (2006).
   PubMed Web of Science ®Google Scholar
• Prakash M, Patterson S, Kapembwa MS. Evaluation of the cervical cytobrush sampling technique for the preparation of CD45+ mononuclear cells from the human cervix. J. Immunol. Methods258, 37–46 (2001).
   PubMedGoogle Scholar
• Biasin M, Caputo SL, Speciale L et al. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J. Infect. Dis.182, 1365–1374 (2000).
   PubMedGoogle Scholar
• Kaul R, Plummer FA, Kimani J et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol.164, 1602–1611 (2000).
   PubMed Web of Science ®Google Scholar
• Gumbi PP, Nkwanyana NN, Bere A et al. Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J. Virol.82, 8529–8536 (2008).
   PubMedGoogle Scholar
• Rebbapragada A, Wachihi C, Pettengell C et al. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. Aids21, 589–598 (2007).
   PubMedGoogle Scholar
• Levine WC, Pope V, Bhoomkar A et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J. Infect. Dis.177, 167–174 (1998).
   PubMed Web of Science ®Google Scholar
• Huskens D, Vermeire K, Profy AT, Schols D. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res.84, 38–47 (2009).
   PubMedGoogle Scholar
• Hjelmevoll SO, Olsen ME, Sollid JU et al. Clinical validation of a real-time polymerase chain reaction detection of Neisseria gonorrheae porA pseudogene versus culture techniques. Sex Transm. Dis.35, 517–520 (2008).
   PubMedGoogle Scholar
• Mauck CK, Doncel GF. Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV. Contraception75, 407–419 (2007).
   PubMed Web of Science ®Google Scholar
• Kozlowski PA, Williams SB, Lynch RM et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol.169, 566–574 (2002).
   PubMed Web of Science ®Google Scholar
• Crucitti T, Jespers V, Van Damme L, Van Dyck E, Buve A. Vaginal microbicides can interfere with nucleic acid amplification tests used for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infection. Diagn. Microbiol. Infect Dis.57, 97–99 (2007).
   PubMedGoogle Scholar
• Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol.172, 6209–6220 (2004).
   PubMed Web of Science ®Google Scholar
• Barassi C, Soprana E, Pastori C et al. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J. Virol.79, 6848–6858 (2005).
   PubMedGoogle Scholar
• Buonaguro L, Visciano ML, Tornesello ML et al. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol.79, 7059–7067 (2005).
   PubMed Web of Science ®Google Scholar
• Brave A, Hallengard D, Schroder U et al. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses. Vaccine26, 5075–5078 (2008).
   PubMed Web of Science ®Google Scholar
• Medaglini D, Oggioni MR, Pozzi G. Vaginal immunization with recombinant Gram-positive bacteria. Am. J. Reprod. Immunol.39, 199–208 (1998).
   PubMed Web of Science ®Google Scholar
• VanCott TC, Kaminski RW, Mascola JR et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol.160, 2000–2012 (1998).
   PubMed Web of Science ®Google Scholar
• Ciabattini A, Giomarelli B, Parigi R et al. Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA. Vaccine26, 4244–4250 (2008).
   PubMed Web of Science ®Google Scholar
• Spetz AL, Sorensen AS, Walther-Jallow L et al. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells. J. Immunol.169, 5771–5779 (2002).
   PubMed Web of Science ®Google Scholar
• Brave A, Johansson U, Hallengard D et al. Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine28(9), 2080–2087 (2009).
   PubMedGoogle Scholar
• Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol.182, 6435–6443 (2009).
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang M, Zhou C et al. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J. Immunol.180, 2504–2513 (2008).
   PubMed Web of Science ®Google Scholar
• Curran RM, Donnelly L, Morrow RJ et al. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine27, 6791–6798 (2009).
   PubMed Web of Science ®Google Scholar
• Cranage MP, Fraser CA, Stevens Z et al. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol.3, 57–68 (2009).
   PubMedGoogle Scholar
• Wang Y, Abel K, Lantz K et al. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol.79, 14355–14370 (2005).
   PubMed Web of Science ®Google Scholar
• Miller CJ, Kang DW, Marthas M et al. Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques. Clin. Exp. Immunol.88, 520–526 (1992).
   PubMedGoogle Scholar
• Lehner T, Bergmeier LA, Tao L et al. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J. Immunol.153, 1858–1868 (1994).
   PubMedGoogle Scholar
• Lu FX, Ma Z, Rourke T, Srinivasan S et al. Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle. Infect. Immun.67, 6321–6328 (1999).
   PubMedGoogle Scholar
• Corbett M, Bogers WM, Heeney JL et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc. Natl Acad. Sci. USA105, 2046–2051 (2008).
   PubMed Web of Science ®Google Scholar
• Bogers WM, Bergmeier LA, Ma J et al. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. AIDS18, 25–36 (2004).
   PubMedGoogle Scholar
• Hidajat R, Xiao P, Zhou Q et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol.83, 791–801 (2009).
   PubMed Web of Science ®Google Scholar
• Shacklett BL, Cu-Uvin S, Beadle TJ et al. Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface. AIDS14, 1911–1915 (2000).
   PubMedGoogle Scholar
• Hobbs MM, Steiner MJ, Rich KD et al. Good performance of rapid prostate-specific antigen test for detection of semen exposure in women: implications for qualitative research. Sex Transm. Dis.36, 501–506 (2009).
   PubMedGoogle Scholar
• Raux M, Finkielsztejn L, Salmon-Ceron D et al. Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. J. Immunol. Methods222, 111–124 (1999).
   PubMed Web of Science ®Google Scholar
• Ghys PD, Belec L, Diallo MO et al. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d’Ivoire. AIDS14, 2603–2608 (2000).
   PubMedGoogle Scholar
• Belec L, Ghys PD, Hocini H et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis.184, 1412–1422 (2001).
   PubMed Web of Science ®Google Scholar
• Mestecky J, Jackson S, Moldoveanu Z et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses20, 972–988 (2004).
   PubMed Web of Science ®Google Scholar
• Wassen L, Jertborn M. Influence of exogenous reproductive hormones on specific antibody production in genital secretions after vaginal vaccination with recombinant cholera toxin B subunit in humans. Clin. Vaccine Immunol.13, 202–207 (2006).
   PubMedGoogle Scholar
• Hordnes K, Trovik J, Tynning T, Haneberg B. Self-sampled and air-dried cervicovaginal secretions can be used for analyses of mucosal antibodies. J. Immunol. Methods220, 151–159 (1998).
   PubMedGoogle Scholar
• Hirbod T, Kaul R, Reichard C et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS22, 727–735 (2008).
   PubMedGoogle Scholar
• Rohan LC, Edwards RP, Kelly LA et al. Optimization of the Weck-Cel collection method for quantitation of cytokines in mucosal secretions. Clin. Diagn. Lab. Immunol.7, 45–48 (2000).
   PubMedGoogle Scholar
• Levinson P, Kaul R, Kimani J et al. Levels of innate immune factors in genital fluids: association of a defensins and LL-37 with genital infections and increased HIV acquisition. AIDS23, 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• Benki S, McClelland RS, Emery S et al. Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J. Clin. Microbiol.44, 4357–4362 (2006).
   PubMedGoogle Scholar
• Boskey ER, Moench TR, Hees PS, Cone RA. A self-sampling method to obtain large volumes of undiluted cervicovaginal secretions. Sex Transm. Dis.30, 107–109 (2003).
   PubMedGoogle Scholar
• Cohen CR, Plummer FA, Mugo N et al. Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? AIDS13, 327–332 (1999).
   PubMedGoogle Scholar
• Musey L, Hu Y, Eckert L et al. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J. Exp. Med.185, 293–303 (1997).
   PubMed Web of Science ®Google Scholar
• Kaul R, Thottingal P, Kimani J et al. Quantitative ex vivo analysis of functional virus-specific CD8 T lymphocytes in the blood and genital tract of HIV-infected women. AIDS17, 1139–1144 (2003).
   PubMedGoogle Scholar
• Hirbod T, Kaldensjo T, Lopalco L et al. Abundant and superficial expression of C-type lectin receptors in ectocervix of women at risk of HIV infection. J. Acquir. Immune Defic. Syndr.51, 239–247 (2009).
   PubMedGoogle Scholar
• McGowan I, Elliott J, Cortina G et al. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J. Acquir. Immune Defic. Syndr.46, 417–425 (2007).
   PubMedGoogle Scholar
• Wright PF, Kozlowski PA, Rybczyk GK et al. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res. Hum. Retroviruses18, 1291–1300 (2002).
   PubMedGoogle Scholar
• Critchfield JW, Lemongello D, Walker DH et al. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J. Virol.81, 5460–5471 (2007).
   PubMedGoogle Scholar
• Shacklett BL, Critchfield JW, Lemongello D. Isolating mucosal lymphocytes from biopsy tissue for cellular immunology assays. Methods Mol. Biol.485, 347–356 (2009).
   PubMedGoogle Scholar
• Olsson J, Poles M, Spetz AL et al. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and β-chemokines. J. Infect. Dis.182, 1625–1635 (2000).
   PubMedGoogle Scholar
• Ibarrondo FJ, Anton PA, Fuerst M et al. Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J. Virol.79, 4289–4297 (2005).
   PubMedGoogle Scholar